The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer

Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer, leading to improved overall survival. However, acquired resistance inevitably occurs. We aimed to identify, quantify, and assess the mechanisms of acquired resistance to trastuzumab. We established an acquired t...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Alonso, Paula, Zazo, Sandra, Martín-Aparicio, Ester, Luque, Melani, Chamizo, Cristina, Sanz-Álvarez, Marta, Minguez, Pablo, Gómez-López, Gonzalo, Cristóbal, Ion, Caramés, Cristina, García-Foncillas, Jesús, Eroles, Pilar, Lluch, Ana, Arpí, Oriol, Rovira, Ana, Albanell, Joan, Piersma, Sander R., Jimenez, Connie R., Madoz-Gúrpide, Juan, Rojo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281325/
https://www.ncbi.nlm.nih.gov/pubmed/32365528
http://dx.doi.org/10.3390/cancers12051108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281325/
https://www.ncbi.nlm.nih.gov/pubmed/32365528
http://dx.doi.org/10.3390/cancers12051108

Ejemplares similares